PRIMARY STUDY
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder
Key Findings: A study evaluating four novel antipsychotic agents found that a neurokinin (NK3) antagonist and a serotonin 2A/2C (5-HT2A/2C) antagonist showed evidence of efficacy in treating schizophrenia and schizoaffective disorder, while a central cannabinoid (CB1) antagonist (SR141716) and a neurotensin (NTS1) antagonist did not demonstrate significant improvement over placebo.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 481
Study Result: Negative
Research Location(s): United States
Year of Pub: 2004
Cannabinoids Studied: SR-x Synthetic Cannabinoids
Phytocannabinoid Source: Not Applicable
Ligands Studied: Serotonin
Citation: Meltzer HY, et al. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004; 161:975-84. doi: 10.1176/appi.ajp.161.6.975
Authors: Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group
